var data={"title":"Shigella infection: Treatment and prevention in children","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Shigella infection: Treatment and prevention in children</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/contributors\" class=\"contributor contributor_credentials\">Shai Ashkenazi, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 20, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Shigella</em> infections are a major cause of pediatric morbidity and mortality worldwide. (See <a href=\"topic.htm?path=shigella-infection-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Shigella infection: Epidemiology, microbiology, and pathogenesis&quot;</a>.)</p><p><em>Shigella</em> infection is characterized by high fever (&gt;38.5&deg;C [101.3&deg;F]), abdominal cramps, diarrhea, tenesmus, and polymorphonuclear leukocytes on a <a href=\"topic.htm?path=methylene-blue-pediatric-drug-information\" class=\"drug drug_pediatric\">methylene blue</a> stain of the stool; extraintestinal manifestations and complications also occur (<a href=\"image.htm?imageKey=ID%2F69134\" class=\"graphic graphic_table graphicRef69134 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/1\" class=\"abstract_t\">1</a>]. Definitive diagnosis requires a stool culture. The characteristic small-volume, <span class=\"nowrap\">bloody/mucous</span> stools are present in approximately one-half of the children with shigellosis [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/1\" class=\"abstract_t\">1</a>]. Neonates [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/2\" class=\"abstract_t\">2</a>] and children with underlying immune deficiency (including HIV infection) [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/3,4\" class=\"abstract_t\">3,4</a>] or malnutrition [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/5,6\" class=\"abstract_t\">5,6</a>] are at increased risk of bacteremia and other complications of shigellosis. (See <a href=\"topic.htm?path=shigella-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Shigella infection: Clinical manifestations and diagnosis&quot;</a>.)</p><p>The treatment of and prevention of <em>Shigella</em> infection in children will be reviewed here. The microbiology, epidemiology, pathogenesis, clinical manifestations, and diagnosis of <em>Shigella </em>infection in children are discussed separately, as is the treatment of <em>Shigella</em> in adults. (See <a href=\"topic.htm?path=shigella-infection-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Shigella infection: Epidemiology, microbiology, and pathogenesis&quot;</a> and <a href=\"topic.htm?path=shigella-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Shigella infection: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=shigella-infection-treatment-and-prevention-in-adults\" class=\"medical medical_review\">&quot;Shigella infection: Treatment and prevention in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H583353163\"><span class=\"h1\">NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infection with <em>Shigella</em> generally is self-limited; the average duration of gastrointestinal symptoms in untreated <em>Shigella</em> gastroenteritis is approximately seven days [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/7\" class=\"abstract_t\">7</a>]. In the absence of specific antibiotic treatment, children with <em>Shigella</em> gastroenteritis shed the organism for up to four weeks; children with immune deficiency shed for much longer periods, even if their symptoms have resolved [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/1,3,4\" class=\"abstract_t\">1,3,4</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">SUPPORTIVE THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Correction of fluid and electrolyte losses is the mainstay of treatment of acute gastroenteritis in children, no matter the cause [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/1\" class=\"abstract_t\">1</a>]. Oral rehydration is preferred when feasible [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/8\" class=\"abstract_t\">8</a>], but intravenous fluids may be necessary. Fluid repletion in children is discussed separately. (See <a href=\"topic.htm?path=oral-rehydration-therapy\" class=\"medical medical_review\">&quot;Oral rehydration therapy&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Treatment of hypovolemia (dehydration) in children&quot;</a>.)</p><p>Early restoration of oral intake, especially protein, is important to prevent malnutrition, particularly in resource-limited countries [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/9-11\" class=\"abstract_t\">9-11</a>]. In addition, the administration of <a href=\"topic.htm?path=vitamin-a-pediatric-drug-information\" class=\"drug drug_pediatric\">vitamin A</a> or zinc, or the ingestion of unripe, mature green banana fruit, may hasten resolution of symptoms in malnourished children in resource-limited countries [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/12-16\" class=\"abstract_t\">12-16</a>]. (See <a href=\"topic.htm?path=approach-to-the-child-with-acute-diarrhea-in-resource-limited-countries#H10253534\" class=\"medical medical_review\">&quot;Approach to the child with acute diarrhea in resource-limited countries&quot;, section on 'Vitamins and minerals'</a>.)</p><p>Intestinal antimotility drugs (eg, <a href=\"topic.htm?path=paregoric-pediatric-drug-information\" class=\"drug drug_pediatric\">paregoric</a>, diphenoxylate, <a href=\"topic.htm?path=loperamide-pediatric-drug-information\" class=\"drug drug_pediatric\">loperamide</a>) should be avoided in children with suspected shigellosis [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/17\" class=\"abstract_t\">17</a>]. These drugs may prolong the duration of fever, diarrhea, and excretion of the organism [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/18\" class=\"abstract_t\">18</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ANTIBIOTIC RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antibiotic susceptibility testing is essential for management of patients with suspected <em>Shigella</em> infection. Antimicrobial resistance is relatively high and patterns of resistance vary geographically [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/19-22\" class=\"abstract_t\">19-22</a>].</p><p>In the United States, antimicrobial resistance is an increasing problem. Among the 531 isolates tested by the National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria during 2014, the following results were reported [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/23\" class=\"abstract_t\">23</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most isolates (95 to 99 percent) were susceptible to <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a>, <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a>, and <a href=\"topic.htm?path=ciprofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">ciprofloxacin</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thirty-four percent of isolates were resistant to <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>, 41 percent to <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a>, and 6 percent to nalidixic acid.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Forty-two percent of isolates were resistant to &ge;3 Clinical and Laboratory Standards Institute antimicrobial classes.</p><p/><p>Reports of strains resistant to nalidixic acid, <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a>, <a href=\"topic.htm?path=ciprofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">ciprofloxacin</a>, and <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> are increasing [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/21,24-30\" class=\"abstract_t\">21,24-30</a>]. Some, but not all, of these cases were associated with international travel or adoption. Decreased susceptibility to azithromycin (minimum inhibitory concentration [MIC] &gt;16 <span class=\"nowrap\">mcg/mL)</span> has also been detected in several <em>S. sonnei</em> outbreaks and sporadic cases throughout the United States, predominantly among men who have sex with men [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/27,31-35\" class=\"abstract_t\">27,31-35</a>]. Scattered infections with extremely drug-resistant isolates that are ciprofloxacin-resistant and have decreased susceptibility to azithromycin have also been reported [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/36\" class=\"abstract_t\">36</a>].</p><p>Species-, state-, and antibiotic-specific resistance information is available from <a href=\"http://wwwn.cdc.gov/narmsnow/&amp;token=or3eUlpzJzn0H2eHuzyjqTI0yCZkQgh5wVCwHFHyUEDhciD4A56fn0z2GkZe4dK4&amp;TOPIC_ID=6003\" target=\"_blank\" class=\"external\">NARMS Now</a>, an interactive tool provided by the Centers for Disease Control and Prevention [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/37\" class=\"abstract_t\">37</a>].</p><p>In Europe, resistance to nalidixic acid, <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a>, and <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> have been reported [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/38,39\" class=\"abstract_t\">38,39</a>] but are uncommon.</p><p>In India and Bangladesh, 20 percent or more of isolates are resistant to nalidixic acid [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/40-42\" class=\"abstract_t\">40-42</a>]. Increasing levels of resistance to <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> and <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> have also been reported in Asia [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/43,44\" class=\"abstract_t\">43,44</a>].</p><p>A systematic review compared resistance of <em>Shigella</em> isolates to third-generation cephalosporins between Asia-Africa and Europe-America [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/45\" class=\"abstract_t\">45</a>]. During 2010-2012, in Asia-Africa, 14 percent of isolates were resistant to <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a>, 23 percent to <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, and 6 percent to <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftazidime</a>, compared with &lt;1 percent of isolates in Europe-America. Resistance to third-generation cephalosporins was especially high in Vietnam, China, and Iran.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">ANTIBIOTIC THERAPY</span></p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Rationale</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goals of antibiotic therapy for <em>Shigella</em> include improvement in symptoms and eradication of the organism, which may result in decreased spread of infection.</p><p>In randomized trials, appropriate antimicrobial treatment of <em>Shigella</em> gastroenteritis improves diarrhea (by approximately three days), fever (by approximately one day) and reduces shedding (two to five days versus up to four weeks if untreated) [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/46-50\" class=\"abstract_t\">46-50</a>]. It is uncertain whether antibiotic therapy prevents relapse [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/50\" class=\"abstract_t\">50</a>]. Appropriate antimicrobial treatment also may reduce the risk of developing complications [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/47,51\" class=\"abstract_t\">47,51</a>]. (See <a href=\"#H583353163\" class=\"local\">'Natural history'</a> above and <a href=\"topic.htm?path=shigella-infection-clinical-manifestations-and-diagnosis#H3\" class=\"medical medical_review\">&quot;Shigella infection: Clinical manifestations and diagnosis&quot;, section on 'Intestinal complications'</a> and <a href=\"topic.htm?path=shigella-infection-clinical-manifestations-and-diagnosis#H8\" class=\"medical medical_review\">&quot;Shigella infection: Clinical manifestations and diagnosis&quot;, section on 'Systemic complications'</a>.)</p><p>These benefits outweigh the potential risk of promoting the development of resistant organisms. Serious adverse effects may occur with antibiotics used to treat <em>Shigella</em> (eg, anaphylaxis, hypersensitivity, Stevens-Johnson syndrome). However, in a 2010 meta-analysis of 16 trials (1748 pediatric and adult participants), all of the antibiotics were found to be safe; no serious adverse effects were reported. Antimicrobial therapy does not appear to increase the risk of <em>S. dysenteriae</em>-related hemolytic-uremic syndrome (HUS) [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/52\" class=\"abstract_t\">52</a>], in contrast with cytotoxin-producing (enterohemorrhagic) <em>Escherichia coli</em>-related HUS. (See <a href=\"topic.htm?path=shigella-infection-clinical-manifestations-and-diagnosis#H14\" class=\"medical medical_review\">&quot;Shigella infection: Clinical manifestations and diagnosis&quot;, section on 'Hemolytic-uremic syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Decisions regarding initiation of antimicrobial therapy must consider the clinical condition of the patient, host factors that predispose to more severe infection, and public health considerations. <em>Shigella</em> is highly contagious &ndash; ingestion of as few as 10 organisms can produce disease [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/53\" class=\"abstract_t\">53</a>]. Thus, eradication of the organism from children and adolescents at risk to transmit the disease to others (eg, a day care attendee, hospitalized patient) is particularly compelling.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Immunocompromised or ill patients</strong> &ndash; We recommend <strong>empiric</strong> antimicrobial therapy for shigellosis in children and adolescents who present with <strong>suspected shigellosis</strong> (eg, <span class=\"nowrap\">bloody/mucous</span> diarrhea, abdominal cramping, high fever, polymorphonuclear leukocytes on a <a href=\"topic.htm?path=methylene-blue-pediatric-drug-information\" class=\"drug drug_pediatric\">methylene blue</a> stain of the stool) <strong>and</strong> [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/5,54\" class=\"abstract_t\">5,54</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Are immunocompromised</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Have clinical features that may suggest bacteremia (leukocytosis, hypothermia, temperature &gt;39&ordm;C [102.2&ordm;F], lethargy)</p><p/><p class=\"bulletIndent1\">For these patients, antibiotics should be started empirically &ndash; after obtaining stool, and if needed also blood culture &ndash; and then modified as needed based upon susceptibility testing. (See <a href=\"#H7\" class=\"local\">'Choice of regimen'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Symptomatic patients with culture-proven </strong><strong><em>Shigella</em></strong><strong> </strong>&ndash; We recommend antimicrobial therapy for children and adolescents with <strong>symptomatic culture-proven</strong> <em>Shigella</em> who:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Have documented bacteremia</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Require hospitalization</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Attend day care</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Live in institutions</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Are involved in food handling</p><p/><p class=\"bulletIndent1\">For other symptomatic patients, antimicrobial therapy also may be warranted, but the decision depends upon the severity of illness and risk of transmitting infection to others.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Suspected </strong><strong><em>Shigella</em></strong> &ndash; We suggest antimicrobial therapy for <strong>symptomatic</strong> children and adolescents who do not fall into one of the above categories and have one of the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Suspected shigellosis according to epidemiologic data (eg, outbreak setting, positive culture in household or day care contact, etc)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Suspected shigellosis on clinical basis <span class=\"nowrap\">(bloody/mucous</span> diarrhea, high fever)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mild disease or recently recovered</strong> &ndash; We do not recommend antimicrobial therapy for most children with mild disease or spontaneous recovery. We suggest antimicrobial therapy for children with mild disease or children who have recovered from <em>Shigella</em> by the time the report of positive <em>Shigella</em> culture is available if they are hospitalized, attend day care centers, or live in institutions. However such treatment is controversial. Antimicrobial treatment is unlikely to significantly affect the clinical course but will shorten fecal excretion and thus possibly reduce the spread of this highly contagious bacterium.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Choice of regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The empiric antibiotic regimen is determined by host factors, severity of illness, local resistance patterns, and history of travel to an area with increased resistance [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/55,56\" class=\"abstract_t\">55,56</a>]. Empiric therapy is changed as necessary based upon the results of susceptibility testing (which should be performed on all isolates) or if the patient remains symptomatic after &ge;3 days of therapy. (See <a href=\"#H3\" class=\"local\">'Antibiotic resistance'</a> above and <a href=\"#H672227011\" class=\"local\">'Treatment failure'</a> below.)</p><p class=\"headingAnchor\" id=\"H848310686\"><span class=\"h3\">Parenteral versus oral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Parenteral antibiotic therapy is indicated for children with proven or suspected shigellosis who:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Have underlying immune deficiency; shigellosis in children with immune deficiency, including acquired immunodeficiency syndrome, is associated with a prolonged course, increased risk of complications, and prolonged shedding</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Have severe toxemia or suspected bacteremia (signs of bacteremia include leukocytosis, hypothermia, temperature &gt;39&ordm;C [102.2&ordm;F], and lethargy [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/5\" class=\"abstract_t\">5</a>]); bacteremia is associated with increased mortality (see <a href=\"topic.htm?path=shigella-infection-clinical-manifestations-and-diagnosis#H8\" class=\"medical medical_review\">&quot;Shigella infection: Clinical manifestations and diagnosis&quot;, section on 'Systemic complications'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Are unable to take oral medications (vomiting, stupor, etc)</p><p/><p class=\"headingAnchor\" id=\"H848310652\"><span class=\"h3\">Parenteral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For children &lt;18 years of age with proven or suspected shigellosis in whom the antibiotic susceptibility of the isolate is unknown, we suggest <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> 50 <span class=\"nowrap\">mg/kg</span> per day intravenously (IV) in a single daily dose (maximum 1.5 g) for five days as the first-line parenteral therapy. Patients who do not have immune deficiency or bacteremia and are afebrile after two days may be treated for two rather than five days [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/57\" class=\"abstract_t\">57</a>]. In comparative studies, two days of ceftriaxone was as effective as five days [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/57,58\" class=\"abstract_t\">57,58</a>]. However, a single dose of ceftriaxone did not eradicate <em>Shigella</em> from the stool in adult patients [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/58\" class=\"abstract_t\">58</a>].</p><p><a href=\"topic.htm?path=ciprofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ciprofloxacin</a> 10 <span class=\"nowrap\">mg/kg</span> IV (maximum 400 <span class=\"nowrap\">mg/dose)</span> every 12 hours for five days is an alternative to <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> for patients &ge;18 years and for those with contraindications to ceftriaxone [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/7,59,60\" class=\"abstract_t\">7,59,60</a>]. Fluoroquinolone use in children &lt;18 years should be reserved for patients in whom there is no other safe and effective alternative [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/61\" class=\"abstract_t\">61</a>]. (See <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>.)</p><p>Both <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> and <a href=\"topic.htm?path=ciprofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">ciprofloxacin</a> achieve high concentrations in the serum and stool and have activity against <em>Shigella</em> and usually against some other bacterial causes of diarrhea (eg, ceftriaxone against<em> Salmonella; </em>ciprofloxacin against<em> Salmonella </em>and <em>Campylobacter</em>) [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/62,63\" class=\"abstract_t\">62,63</a>].</p><p>The benefits of <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> were demonstrated in an open trial in which 40 children (mean age 4.5 years) with severe <em>Shigella</em> dysentery were randomly assigned to IV ceftriaxone 50 <span class=\"nowrap\">mg/kg</span> per day or <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> 100 <span class=\"nowrap\">mg/kg</span> per day for one to two days followed by intramuscular or oral therapy, respectively [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/64\" class=\"abstract_t\">64</a>]. All of the <em>Shigella</em> isolates were sensitive to ceftriaxone, whereas 28 percent were resistant to ampicillin. Children treated with ceftriaxone had shorter mean duration of diarrhea (2.5 versus 6.8 days), greater rates of eradication from the stool after five days (100 versus 60 percent), and fewer bacteriologic relapses (0 versus 40 percent) than those treated with ampicillin.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Oral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral treatment of shigellosis depends upon local resistance patterns. Susceptibility testing should be performed on all isolates and empiric therapy changed as necessary based upon the results, as well as on clinical response because susceptibility testing to <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> is not routinely performed [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/7,39\" class=\"abstract_t\">7,39</a>]. Recommended doses and durations are provided in the table (<a href=\"image.htm?imageKey=PEDS%2F88651\" class=\"graphic graphic_table graphicRef88651 \">table 2</a>).</p><p class=\"headingAnchor\" id=\"H33238857\"><span class=\"h4\">Children &lt;18 years</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Azithromycin</a> is the suggested <strong>first-line</strong> oral treatment of shigellosis in children &lt;18 years of age if the antibiotic susceptibility of the isolate is unknown. In a randomized trial in hospitalized adults with shigellosis, azithromycin was clinically and bacteriologically successful in 82 and 94 percent of recipients, respectively [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/62\" class=\"abstract_t\">62</a>]. However, resistance to azithromycin is increasing in some parts of the world and in certain populations, such as adolescent men who have sex with men [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/27,33\" class=\"abstract_t\">27,33</a>]. Children and adolescents who do not respond to azithromycin may require second-line therapy, guided by susceptibility testing to other antibiotics. (See <a href=\"#H3\" class=\"local\">'Antibiotic resistance'</a> above.)</p><p><a href=\"topic.htm?path=cefixime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefixime</a> or <a href=\"topic.htm?path=ceftibuten-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftibuten</a> may be used as first-line therapy for children who have acquired <em>Shigella</em> in South Asia (eg, India, Pakistan, Bangladesh), where there is widespread resistance to other commonly used drugs, including <a href=\"topic.htm?path=ciprofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">ciprofloxacin</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a>, and <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/43\" class=\"abstract_t\">43</a>]. Published reports regarding the efficacy of other oral third-generation cephalosporins against shigellosis are lacking.</p><p><strong>Second-line</strong> oral treatment options vary based upon geographic location:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the United States, <a href=\"topic.htm?path=cefixime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefixime</a> or <a href=\"topic.htm?path=ceftibuten-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftibuten</a> is an alternative to <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> in children &lt;18 years [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/65-67\" class=\"abstract_t\">65-67</a>]. However, experience with these agents is limited, and, in an open randomized trial, azithromycin was more effective than cefixime in bacterial eradication [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/68\" class=\"abstract_t\">68</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Outside the United States, nalidixic acid (not available in the United States) is an alternative to <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> in regions with low levels of resistance. However, nalidixic acid must be given four times per day. In addition, in studies in children and adults, nalidixic acid was inferior to fluoroquinolones and azithromycin in reducing duration of diarrhea <span class=\"nowrap\">and/or</span> eradication of the organism from the stool [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/69-72\" class=\"abstract_t\">69-72</a>].</p><p/><p class=\"bulletIndent1\">Pivmecillinam (an extended spectrum penicillin, also not available in the United States) is another alternative to <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a>. In randomized trials and systematic reviews, it was effective in reducing duration of diarrhea and eradication of the organism from the stool [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/55,60,73\" class=\"abstract_t\">55,60,73</a>]. However, pivmecillinam must be given four times per day [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/55\" class=\"abstract_t\">55</a>].</p><p/><p>For children &lt;18 years, fluoroquinolones (eg, <a href=\"topic.htm?path=ciprofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">ciprofloxacin</a>, <a href=\"topic.htm?path=norfloxacin-united-states-not-available-drug-information\" class=\"drug drug_general\">norfloxacin</a> [not available in the United States]) are reserved for <em>Shigella</em> caused by isolates resistant to other oral antibiotics [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/61\" class=\"abstract_t\">61</a>]. <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Trimethoprim-sulfamethoxazole</a> or <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> should be used only if the isolated strain is known to be susceptible given the high worldwide resistance. (See <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>.)</p><p class=\"headingAnchor\" id=\"H33238912\"><span class=\"h4\">Adolescents &ge;18 years</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to the treatment of <em>Shigella</em> in adolescents &ge;18 years is the same as that for adults. (See <a href=\"topic.htm?path=shigella-infection-treatment-and-prevention-in-adults\" class=\"medical medical_review\">&quot;Shigella infection: Treatment and prevention in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H848310421\"><span class=\"h1\">FOLLOW-UP</span></p><p class=\"headingAnchor\" id=\"H672227549\"><span class=\"h2\">Treatment response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Improvement (eg, fewer stools, less blood in the stools, lower fever, improved appetite) is expected within one to two days if <em>Shigella</em> infection is treated with an antibiotic to which the isolate is susceptible [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/55,74\" class=\"abstract_t\">55,74</a>].</p><p class=\"headingAnchor\" id=\"H672227011\"><span class=\"h2\">Treatment failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment failure is defined by persistent or worsening fever, grossly bloody stools, or unchanged stool frequency by Day 3 of therapy [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/74\" class=\"abstract_t\">74</a>]. Treatment failure suggests a resistant organism or <span class=\"nowrap\">other/additional</span> pathogen. Stool cultures should be obtained in patients with treatment failure [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/30\" class=\"abstract_t\">30</a>]. Antibiotic therapy should be changed accordingly, based upon culture and susceptibility results. Morbidity and mortality are increased in patients in whom the isolate is not susceptible to the initial antimicrobial agent [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/75,76\" class=\"abstract_t\">75,76</a>].</p><p class=\"headingAnchor\" id=\"H848310476\"><span class=\"h2\">Test of cure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not routinely necessary to obtain stool cultures after appropriate antibiotic therapy in patients who recovered clinically. However, follow-up cultures may be necessary to prevent spread of infection in specific settings (eg, among food-handlers, child care attendees or staff members).</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">PREVENTION</span></p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">General measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>General recommendations for the prevention of <em>Shigella</em> infections include the use of safe drinking water, chlorination of unreliable water sources, strict hand washing, and refrigeration and proper cooking of food. A meta-analysis of clinical studies suggested that hand washing with soap reduces the risk of shigellosis by 59 percent [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/77\" class=\"abstract_t\">77</a>].</p><p>Food handlers infected with <em>Shigella</em> must be treated with antibiotics and should not be involved in the preparation of food until their stool cultures are negative, which generally requires at least 48 hours of antibiotic treatment. (See <a href=\"#H6\" class=\"local\">'Indications'</a> above.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Isolation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to standard precautions, contact precautions are indicated for the duration of illness with or hospitalization for <em>Shigella</em> infection [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H2\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Standard precautions'</a> and <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H954996324\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Contact precautions'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">School or day care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If <em>Shigella</em> infection occurs in a child attending day care or in a staff member, stool cultures should be obtained from other symptomatic day care attendees, staff members, and household contacts [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/54\" class=\"abstract_t\">54</a>]. The local health department should be contacted to assess and manage potential outbreaks.</p><p>Symptomatic persons with positive stool cultures should be excluded from the child care center until appropriate antibiotic therapy is initiated and &ge;24 hours after diarrhea has resolved and, depending upon local regulations, until one or more stool cultures are negative for <em>Shigella</em>.</p><p>Additional control measures for day schools and day care centers include [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/36,78-80\" class=\"abstract_t\">36,78-80</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Appropriate hand washing and diapering practices</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scheduling hand washing sessions on arrival at the day care center, before meals, or after playing outdoors</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Supervised hand washing for young children</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eliminating water play areas</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Vaccine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A vaccine against shigellosis is not yet available, though this is an area of active investigation [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/81-83\" class=\"abstract_t\">81-83</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Antibiotic prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We generally do not suggest prophylactic antibiotics to prevent <em>Shigella</em> gastroenteritis in travelers unless the child has an underlying medical illness that predisposes him or her to severe consequences of shigellosis. The use of antibiotics, including <a href=\"topic.htm?path=rifaximin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifaximin</a> (which is not absorbed), to prevent traveler's diarrhea is discussed separately. (See <a href=\"topic.htm?path=travelers-diarrhea-microbiology-epidemiology-and-prevention#H26\" class=\"medical medical_review\">&quot;Travelers' diarrhea: Microbiology, epidemiology, and prevention&quot;, section on 'Chemoprophylaxis'</a>.)</p><p class=\"headingAnchor\" id=\"H583353099\"><span class=\"h1\">MANDATED REPORTING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, laboratory-confirmed cases of shigellosis should be reported to the Centers for Disease Control and Prevention through local and state health departments [<a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/84\" class=\"abstract_t\">84</a>].</p><p class=\"headingAnchor\" id=\"H3293689850\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-acute-diarrhea-in-children\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute diarrhea in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Correction of fluid and electrolyte losses is the mainstay of treatment for acute gastroenteritis in children, no matter the cause. (See <a href=\"topic.htm?path=oral-rehydration-therapy\" class=\"medical medical_review\">&quot;Oral rehydration therapy&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Treatment of hypovolemia (dehydration) in children&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimotility drugs (eg, <a href=\"topic.htm?path=paregoric-pediatric-drug-information\" class=\"drug drug_pediatric\">paregoric</a>, diphenoxylate, <a href=\"topic.htm?path=loperamide-pediatric-drug-information\" class=\"drug drug_pediatric\">loperamide</a>) should be avoided in children with suspected shigellosis. (See <a href=\"#H2\" class=\"local\">'Supportive therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The goals of antibiotic therapy for <em>Shigella</em> include improvement in symptoms and eradication of the organism, which may decrease the spread of infection to contacts. (See <a href=\"#H5\" class=\"local\">'Rationale'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decisions regarding initiation of antimicrobial therapy must consider the clinical condition of the patient, host factors that predispose to more severe infection, and public health considerations. (See <a href=\"#H6\" class=\"local\">'Indications'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For children and adolescents who present with <strong>suspected shigellosis</strong> (eg, <span class=\"nowrap\">bloody/mucous</span> diarrhea, abdominal cramping, high fever, polymorphonuclear leukocytes on a <a href=\"topic.htm?path=methylene-blue-pediatric-drug-information\" class=\"drug drug_pediatric\">methylene blue</a> stain of the stool) <strong>and</strong> are immunocompromised or have clinical features that may suggest bacteremia (leukocytosis, hypothermia, temperature &gt;39&ordm;C [102.2&ordm;F], lethargy), we recommend empiric antimicrobial therapy (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H6\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For children and adolescents with <strong>symptomatic</strong> <strong>culture-proven</strong> <em>Shigella</em> who have bacteremia, require hospitalization, attend day care, live in institutions, or are involved in food handling, we recommend antimicrobial therapy (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H6\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For <strong>symptomatic</strong> children and adolescents with culture-proven shigellosis or suspected shigellosis according to epidemiologic data or clinical presentation, we suggest antimicrobial therapy (<a href=\"grade.htm?i=4\" class=\"grade\">Grade 2A</a>). (See <a href=\"#H6\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The empiric antimicrobial regimen is determined by host factors, severity of illness, local resistance patterns, and history of travel to an area of frequent resistance. Empiric therapy is changed as necessary based upon the results of susceptibility testing, which should be performed on all isolates. (See <a href=\"#H7\" class=\"local\">'Choice of regimen'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Parenteral antimicrobial therapy is indicated for children with proven or suspected shigellosis and one or more of the following: severe toxemia or suspected bacteremia, underlying immune deficiency, inability to take oral medications. We typically use <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> as the first-line parenteral therapy for shigellosis in children &lt;18 years of age if the susceptibility of the isolate is unknown (<a href=\"image.htm?imageKey=PEDS%2F88651\" class=\"graphic graphic_table graphicRef88651 \">table 2</a>). (See <a href=\"#H848310686\" class=\"local\">'Parenteral versus oral therapy'</a> above and <a href=\"#H848310652\" class=\"local\">'Parenteral therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Oral treatment of shigellosis depends upon local resistance patterns. We typically use <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> as the first-line oral treatment of shigellosis in children &lt;18 years of age if the antibiotic susceptibility of the isolate is unknown (<a href=\"image.htm?imageKey=PEDS%2F88651\" class=\"graphic graphic_table graphicRef88651 \">table 2</a>). (See <a href=\"#H9\" class=\"local\">'Oral therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment failure is defined by persistent fever, grossly bloody stools, or unchanged stool frequency by day 3 of therapy. Treatment failure suggests a resistant organism or <span class=\"nowrap\">other/additional</span> pathogen, and antibiotic therapy should be changed accordingly. (See <a href=\"#H672227011\" class=\"local\">'Treatment failure'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Symptomatic persons with stool cultures positive for <em>Shigella</em> should be excluded from day care until treatment is initiated, the diarrhea has resolved, and, depending on local regulations, until stool cultures are negative for <em>Shigella</em>. (See <a href=\"#H14\" class=\"local\">'School or day care'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/1\" class=\"nounderline abstract_t\">Ashkenazi S. Shigella infections in children: new insights. Semin Pediatr Infect Dis 2004; 15:246.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/2\" class=\"nounderline abstract_t\">Viner Y, Miron D, Gottfried E, et al. Neonatal shigellosis. Isr Med Assoc J 2001; 3:964.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/3\" class=\"nounderline abstract_t\">Baer JT, Vugia DJ, Reingold AL, et al. HIV infection as a risk factor for shigellosis. Emerg Infect Dis 1999; 5:820.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/4\" class=\"nounderline abstract_t\">Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S84.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/5\" class=\"nounderline abstract_t\">Struelens MJ, Patte D, Kabir I, et al. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis 1985; 152:784.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/6\" class=\"nounderline abstract_t\">Greenberg D, Marcu S, Melamed R, Lifshitz M. Shigella bacteremia: a retrospective study. Clin Pediatr (Phila) 2003; 42:411.</a></li><li class=\"breakAll\">Ashkenazi S, Cleary TG. Shigella species. In: Principles and Practice of Pediatric Infectious Diseases, 4th ed, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, Edinburgh 2012. p.819.</li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/8\" class=\"nounderline abstract_t\">Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59:132.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/9\" class=\"nounderline abstract_t\">Kabir I, Butler T, Underwood LE, Rahman MM. Effects of a protein-rich diet during convalescence from shigellosis on catch-up growth, serum proteins, and insulin-like growth factor-I. Pediatr Res 1992; 32:689.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/10\" class=\"nounderline abstract_t\">Kabir I, Rahman MM, Haider R, et al. Increased height gain of children fed a high-protein diet during convalescence from shigellosis: a six-month follow-Up study. J Nutr 1998; 128:1688.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/11\" class=\"nounderline abstract_t\">Mazumder RN, Hoque SS, Ashraf H, et al. Early feeding of an energy dense diet during acute shigellosis enhances growth in malnourished children. J Nutr 1997; 127:51.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/12\" class=\"nounderline abstract_t\">Hossain S, Biswas R, Kabir I, et al. Single dose vitamin A treatment in acute shigellosis in Bangladesh children: randomised double blind controlled trial. BMJ 1998; 316:422.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/13\" class=\"nounderline abstract_t\">Roy SK, Raqib R, Khatun W, et al. Zinc supplementation in the management of shigellosis in malnourished children in Bangladesh. Eur J Clin Nutr 2008; 62:849.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/14\" class=\"nounderline abstract_t\">Rabbani GH, Ahmed S, Hossain I, et al. Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled clinical trial. Pediatr Infect Dis J 2009; 28:420.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/15\" class=\"nounderline abstract_t\">Rabbani GH, Teka T, Zaman B, et al. Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children. Gastroenterology 2001; 121:554.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/16\" class=\"nounderline abstract_t\">Rabbani GH, Teka T, Saha SK, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea. Dig Dis Sci 2004; 49:475.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/17\" class=\"nounderline abstract_t\">Kotloff KL, Riddle MS, Platts-Mills JA, et al. Shigellosis. Lancet 2018; 391:801.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/18\" class=\"nounderline abstract_t\">DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/19\" class=\"nounderline abstract_t\">Kruse H, Kariuki S, S&oslash;li N, Olsvik O. Multiresistant Shigella species from African AIDS patients: antibacterial resistance patterns and application of the E-test for determination of minimum inhibitory concentration. Scand J Infect Dis 1992; 24:733.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/20\" class=\"nounderline abstract_t\">Ashkenazi S, Levy I, Kazaronovski V, Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 2003; 51:427.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/21\" class=\"nounderline abstract_t\">Sivapalasingam S, Nelson JM, Joyce K, et al. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother 2006; 50:49.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/22\" class=\"nounderline abstract_t\">Shiferaw B, Solghan S, Palmer A, et al. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010. Clin Infect Dis 2012; 54 Suppl 5:S458.</a></li><li class=\"breakAll\">CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Surveillance Report for 2014 (Final Report). US Department of Health and Human Services, Atlanta, GA 2016. http://www.cdc.gov/narms/reports/annual-human-isolates-report-2014.html (Accessed on September 01, 2016).</li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/24\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Notes from the field: emergence of Shigella flexneri 2a resistant to ceftriaxone and ciprofloxacin --- South Carolina, October 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1619.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/25\" class=\"nounderline abstract_t\">Wong MR, Reddy V, Hanson H, et al. Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009. Microb Drug Resist 2010; 16:155.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/26\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Notes from the field: Outbreak of infections caused by Shigella sonnei with decreased susceptibility to azithromycin--Los Angeles, California, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:171.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/27\" class=\"nounderline abstract_t\">Heiman KE, Karlsson M, Grass J, et al. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR Morb Mortal Wkly Rep 2014; 63:132.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/28\" class=\"nounderline abstract_t\">Heiman KE, Grass JE, Sj&ouml;lund-Karlsson M, Bowen A. Shigellosis with decreased susceptibility to azithromycin. Pediatr Infect Dis J 2014; 33:1204.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/29\" class=\"nounderline abstract_t\">Bowen A, Hurd J, Hoover C, et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015. MMWR Morb Mortal Wkly Rep 2015; 64:318.</a></li><li class=\"breakAll\">CDC recommendations for diagnosing and managing Shigella strains with possible reduced susceptibility to ciprofloxacin https://emergency.cdc.gov/han/han00401.asp (Accessed on April 19, 2017).</li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/31\" class=\"nounderline abstract_t\">Howie RL, Folster JP, Bowen A, et al. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb Drug Resist 2010; 16:245.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/32\" class=\"nounderline abstract_t\">Sj&ouml;lund Karlsson M, Bowen A, Reporter R, et al. Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States. Antimicrob Agents Chemother 2013; 57:1559.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/33\" class=\"nounderline abstract_t\">Bowen A, Eikmeier D, Talley P, et al. Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:597.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/34\" class=\"nounderline abstract_t\">Hines JZ, Pinsent T, Rees K, et al. Notes from the Field: Shigellosis Outbreak Among Men Who Have Sex with Men and Homeless Persons - Oregon, 2015-2016. MMWR Morb Mortal Wkly Rep 2016; 65:812.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/35\" class=\"nounderline abstract_t\">Murray K, Reddy V, Kornblum JS, et al. Increasing antibiotic resistance in Shigella spp. from infected New York City Residents, New York, USA. Emerg Infect Dis 2017; 23.</a></li><li class=\"breakAll\">CDC Health Advisory. Ciprofloxacin- and Azithromycin-Nonsusceptible Shigellosis in the United States. http://emergency.cdc.gov/han/han00379.asp.</li><li class=\"breakAll\">Centers for Disease Control and Prevention. NARMS Now: Human data. http://wwwn.cdc.gov/narmsnow/ (Accessed on August 27, 2015).</li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/38\" class=\"nounderline abstract_t\">Cheasty T, Day M, Threlfall EJ. Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy. Clin Microbiol Infect 2004; 10:1033.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/39\" class=\"nounderline abstract_t\">Boumghar-Bourtchai L, Mariani-Kurkdjian P, Bingen E, et al. Macrolide-resistant Shigella sonnei. Emerg Infect Dis 2008; 14:1297.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/40\" class=\"nounderline abstract_t\">Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992; 14:1055.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/41\" class=\"nounderline abstract_t\">Munshi MH, Sack DA, Haider K, et al. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987; 2:419.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/42\" class=\"nounderline abstract_t\">Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis 1991; 13 Suppl 4:S332.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/43\" class=\"nounderline abstract_t\">Rahman M, Shoma S, Rashid H, et al. Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. J Health Popul Nutr 2007; 25:158.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/44\" class=\"nounderline abstract_t\">Kuo CY, Su LH, Perera J, et al. Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004. J Microbiol Immunol Infect 2008; 41:107.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/45\" class=\"nounderline abstract_t\">Gu B, Zhou M, Ke X, et al. Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012. Epidemiol Infect 2015; 143:2687.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/46\" class=\"nounderline abstract_t\">Haltalin KC, Nelson JD, Ring R 3rd, et al. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 1967; 70:970.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/47\" class=\"nounderline abstract_t\">Haltalin KC, Kusmiesz HT, Hinton LV, Nelson JD. Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo. Am J Dis Child 1972; 124:554.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/48\" class=\"nounderline abstract_t\">Garcia de Olarte D, Trujillo H, Agudelo N, et al. Treatment of diarrhea in malnourished infants and children. A double-blind study comparing ampicillin and placebo. Am J Dis Child 1974; 127:379.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/49\" class=\"nounderline abstract_t\">Nelson JD, Haltalin KC. Broad-spectrum penicillins in enteric infections of children. Ann N Y Acad Sci 1967; 145:414.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/50\" class=\"nounderline abstract_t\">Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010; :CD006784.</a></li><li class=\"breakAll\">Ashkenazi S. Shigella species. In: Antimicrobial therapy and vaccines, 2nd ed, Yu VL, Weer R, Raoult D (Eds), Apple Tree Production, New York 2002. p.615.</li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/52\" class=\"nounderline abstract_t\">Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/53\" class=\"nounderline abstract_t\">DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159:1126.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Shigella infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.706.</li><li class=\"breakAll\">World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1 http://whqlibdoc.who.int/publications/2005/9241592330.pdf (Accessed on March 21, 2013).</li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/56\" class=\"nounderline abstract_t\">Lane CR, Sutton B, Valcanis M, et al. Travel Destinations and Sexual Behavior as Indicators of Antibiotic Resistant Shigella Strains--Victoria, Australia. Clin Infect Dis 2016; 62:722.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/57\" class=\"nounderline abstract_t\">Eidlitz-Marcus T, Cohen YH, Nussinovitch M, et al. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr 1993; 123:822.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/58\" class=\"nounderline abstract_t\">Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother 1986; 29:645.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/59\" class=\"nounderline abstract_t\">Lolekha S, Vibulbandhitkit S, Poonyarit P. Response to antimicrobial therapy for shigellosis in Thailand. Rev Infect Dis 1991; 13 Suppl 4:S342.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/60\" class=\"nounderline abstract_t\">Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998; 352:522.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/61\" class=\"nounderline abstract_t\">Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/62\" class=\"nounderline abstract_t\">Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/63\" class=\"nounderline abstract_t\">Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162:711.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/64\" class=\"nounderline abstract_t\">Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 1991; 118:627.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/65\" class=\"nounderline abstract_t\">Ashkenazi S, Amir J, Waisman Y, et al. A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. J Pediatr 1993; 123:817.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/66\" class=\"nounderline abstract_t\">Helvaci M, Bekta&#351;lar D, Ozkaya B, et al. Comparative efficacy of cefixime and ampicillin-sulbactam in shigellosis in children. Acta Paediatr Jpn 1998; 40:131.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/67\" class=\"nounderline abstract_t\">Prado D, L&oacute;pez E, Liu H, et al. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J 1992; 11:644.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/68\" class=\"nounderline abstract_t\">Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003; 22:374.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/69\" class=\"nounderline abstract_t\">Miron D, Torem M, Merom R, Colodner R. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. Pediatr Infect Dis J 2004; 23:367.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/70\" class=\"nounderline abstract_t\">Bhattacharya K, Bhattacharya MK, Dutta D, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr 1997; 86:319.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/71\" class=\"nounderline abstract_t\">Rogerie F, Ott D, Vandepitte J, et al. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob Agents Chemother 1986; 29:883.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/72\" class=\"nounderline abstract_t\">Vinh H, Wain J, Chinh MT, et al. Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid. Trans R Soc Trop Med Hyg 2000; 94:323.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/73\" class=\"nounderline abstract_t\">Traa BS, Walker CL, Munos M, Black RE. Antibiotics for the treatment of dysentery in children. Int J Epidemiol 2010; 39 Suppl 1:i70.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/74\" class=\"nounderline abstract_t\">Islam MR, Alam AN, Hussain MS, Mahalanabis D. Effect of antimicrobial (nalidixic acid) therapy in shigellosis and predictive values of outcome variables in patients susceptible or resistant to it. J Trop Med Hyg 1995; 98:121.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/75\" class=\"nounderline abstract_t\">Kagalwalla AF, Khan SN, Kagalwalla YA, et al. Childhood shigellosis in Saudi Arabia. Pediatr Infect Dis J 1992; 11:215.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/76\" class=\"nounderline abstract_t\">Bennish ML, Salam MA, Wahed MA. Enteric protein loss during shigellosis. Am J Gastroenterol 1993; 88:53.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/77\" class=\"nounderline abstract_t\">Curtis V, Cairncross S. Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 2003; 3:275.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/78\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Outbreaks of multidrug-resistant Shigella sonnei gastroenteritis associated with day care centers--Kansas, Kentucky, and Missouri, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/79\" class=\"nounderline abstract_t\">Gangaros EJ. Annotation: a community-focused strategy for the control of day-care center shigellosis. Am J Public Health 1995; 85:763.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/80\" class=\"nounderline abstract_t\">Hoffman RE, Shillam PJ. The use of hygiene, cohorting, and antimicrobial therapy to control an outbreak of shigellosis. Am J Dis Child 1990; 144:219.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/81\" class=\"nounderline abstract_t\">Rahman KM, Arifeen SE, Zaman K, et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 2011; 29:1347.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/82\" class=\"nounderline abstract_t\">Passwell JH, Ashkenzi S, Banet-Levi Y, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2010; 28:2231.</a></li><li><a href=\"https://www.uptodate.com/contents/shigella-infection-treatment-and-prevention-in-children/abstract/83\" class=\"nounderline abstract_t\">Ashkenazi S, Cohen D. An update on vaccines against Shigella. Ther Adv Vaccines 2013; 1:113.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. wwwn.cdc.gov/nndss/ (Accessed on March 06, 2013).</li></ol></div><div id=\"topicVersionRevision\">Topic 6003 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H583353163\" id=\"outline-link-H583353163\">NATURAL HISTORY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">SUPPORTIVE THERAPY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ANTIBIOTIC RESISTANCE</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">ANTIBIOTIC THERAPY</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Rationale</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Indications</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Choice of regimen</a><ul><li><a href=\"#H848310686\" id=\"outline-link-H848310686\">- Parenteral versus oral therapy</a></li><li><a href=\"#H848310652\" id=\"outline-link-H848310652\">- Parenteral therapy</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Oral therapy</a><ul><li><a href=\"#H33238857\" id=\"outline-link-H33238857\">Children &lt;18 years</a></li><li><a href=\"#H33238912\" id=\"outline-link-H33238912\">Adolescents &ge;18 years</a></li></ul></li></ul></li></ul></li><li><a href=\"#H848310421\" id=\"outline-link-H848310421\">FOLLOW-UP</a><ul><li><a href=\"#H672227549\" id=\"outline-link-H672227549\">Treatment response</a></li><li><a href=\"#H672227011\" id=\"outline-link-H672227011\">Treatment failure</a></li><li><a href=\"#H848310476\" id=\"outline-link-H848310476\">Test of cure</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">PREVENTION</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">General measures</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Isolation</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">School or day care</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Vaccine</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Antibiotic prophylaxis</a></li></ul></li><li><a href=\"#H583353099\" id=\"outline-link-H583353099\">MANDATED REPORTING</a></li><li><a href=\"#H3293689850\" id=\"outline-link-H3293689850\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6003|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/69134\" class=\"graphic graphic_table\">- Major complications of Shigella</a></li><li><a href=\"image.htm?imageKey=PEDS/88651\" class=\"graphic graphic_table\">- Antibiotic treatment Shigella children</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-child-with-acute-diarrhea-in-resource-limited-countries\" class=\"medical medical_review\">Approach to the child with acute diarrhea in resource-limited countries</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluoroquinolones\" class=\"medical medical_review\">Fluoroquinolones</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-rehydration-therapy\" class=\"medical medical_review\">Oral rehydration therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=shigella-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Shigella infection: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=shigella-infection-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">Shigella infection: Epidemiology, microbiology, and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=shigella-infection-treatment-and-prevention-in-adults\" class=\"medical medical_review\">Shigella infection: Treatment and prevention in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-diarrhea-in-children\" class=\"medical medical_society_guidelines\">Society guideline links: Acute diarrhea in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=travelers-diarrhea-microbiology-epidemiology-and-prevention\" class=\"medical medical_review\">Travelers' diarrhea: Microbiology, epidemiology, and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">Treatment of hypovolemia (dehydration) in children</a></li></ul></div></div>","javascript":null}